Cannabis is proven to be an effective treatment for pain relief, anxiety, and inflammatory conditions.
However, cannabis does not work like most medications and it’s not legal in every US state. Because there is not a set dosage for treatment plans, monitoring cannabis usage is a challenge for providers.
As studies continue to show patients experiencing relief from cannabis, the use of hemp products, containing CBD and a number of other cannabinoids is rising across the country. Many hemp products contain Delta-8-THC, a THC analogue, that is legal in many states and exhibits less psychoactive potency than Delta-9-THC.
Traditionally, laboratories have only informed physicians if Delta-9-THC is present in a patient’s sample but cannot differentiate Delta-8-THC and its metabolites, leaving clinicians questioning patient usage and proper treatment plans.
Our team of scientists and operational leaders have developed an industry leading algorithm, CannabisConfirm™, to differentiate CBD usage from the use of other cannabis products containing Delta-8-THC. Luxor Scientific is the only lab in the US offering CannabisConfirm™, providing accurate results and 24-hr turnaround times.
Luxor will continue to monitor market trends and expand offerings to respond to the needs of our clinicians.
- CBD sales in the U.S. hit $4.6 billion in 2020, a massive number just two years after hemp-derived cannabinoids were federally legalized.
- Forbes released a study on the CBD market estimating a growth of $16 billion by 2025.
- Delta-8 THC products have seen a significant increase in popularity in the US over the past two years, resulting in over $2 billion in sales as an alternative to “traditional” cannabis.